High-dose cyclophosphamide for graft-versus-host disease prevention
Taking advantage of the differential susceptibility of proliferating, alloreactive T cells over
nonproliferating, nonalloreactive T cells to high-dose cyclophosphamide, and owing to the
drug's stem cell sparing effects, this novel strategy provides a unique opportunity to optimize
GvHD prophylaxis after HLA-matched alloBMT and increase the use of HLA-mismatched
related donors. Well tolerated and effective mismatched related alloBMT provides access to
essentially everyone, such as patients with sickle cell anemia, in need of the procedure.
nonproliferating, nonalloreactive T cells to high-dose cyclophosphamide, and owing to the
drug's stem cell sparing effects, this novel strategy provides a unique opportunity to optimize
GvHD prophylaxis after HLA-matched alloBMT and increase the use of HLA-mismatched
related donors. Well tolerated and effective mismatched related alloBMT provides access to
essentially everyone, such as patients with sickle cell anemia, in need of the procedure.
Summary
Taking advantage of the differential susceptibility of proliferating, alloreactive T cells over nonproliferating, nonalloreactive T cells to high-dose cyclophosphamide, and owing to the drug's stem cell sparing effects, this novel strategy provides a unique opportunity to optimize GvHD prophylaxis after HLA-matched alloBMT and increase the use of HLA-mismatched related donors. Well tolerated and effective mismatched related alloBMT provides access to essentially everyone, such as patients with sickle cell anemia, in need of the procedure.
Lippincott Williams & Wilkins